| 1 |
34727317 | Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. | 2022 Jan |
1 |
| 2 |
32867545 | An evaluation of selexipag for the treatment of pulmonary hypertension. | 2021 Jan |
1 |
| 3 |
33526303 | Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. | 2021 Apr |
1 |
| 4 |
33539988 | Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome. | 2021 Aug |
2 |
| 5 |
33952848 | [Pharmacological characteristics and clinical study results of Selexipag (Uptravi® tablets), a selective prostacyclin receptor agonist]. | 2021 |
2 |
| 6 |
32110381 | Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension. | 2020 Jan-Mar |
1 |
| 7 |
32879152 | Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients　- A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study. | 2020 Sep 25 |
1 |
| 8 |
30671881 | Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol. | 2019 Apr |
1 |
| 9 |
31042010 | Prostacyclin for pulmonary arterial hypertension. | 2019 May 1 |
1 |
| 10 |
28639216 | Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag. | 2018 Feb |
2 |
| 11 |
28737453 | The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag. | 2018 Jul |
1 |
| 12 |
30526673 | Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA). | 2018 Dec 10 |
1 |
| 13 |
28399721 | The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. | 2017 Jun |
1 |
| 14 |
28420826 | Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension. | 2017 Aug 25 |
2 |
| 15 |
28478717 | Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension. | 2017 Jun |
1 |
| 16 |
28494686 | Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension. | 2017 Jun |
1 |
| 17 |
28524738 | Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review. | 2017 Jul |
2 |
| 18 |
26846322 | Selexipag: First Global Approval. | 2016 Mar |
1 |
| 19 |
27062188 | Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. | 2016 Aug |
2 |
| 20 |
27063071 | Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects. | 2016 May |
1 |
| 21 |
27491673 | A Contemporary Approach to Pulmonary Arterial Hypertension. | 2016 Sep |
1 |
| 22 |
27895464 | Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy. | 2016 |
1 |
| 23 |
25850750 | Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. | 2015 Jun |
1 |
| 24 |
25851691 | Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. | 2015 Oct |
1 |
| 25 |
26152132 | Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study. | 2015 Sep |
2 |
| 26 |
26291199 | Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. | 2015 Sep 24 |
1 |
| 27 |
24392948 | Selexipag for the treatment of pulmonary arterial hypertension. | 2014 Feb |
1 |
| 28 |
25277144 | Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. | 2014 |
1 |
| 29 |
22362844 | Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. | 2012 Oct |
1 |